Machine learning heads off unwise eye surgeries

Eyesight researchers have developed a machine-learning architecture whose best model, an ensemble classifier, achieved 93.4% accuracy in separating good candidates for corneal refractive surgery from patients likely to have post-surgery complications or poor outcomes.

The model performed much better than conventional screening methods and as well as highly experienced ophthalmologists who participated in the research.  

The full study was published with open access in npj Digital Medicine.

Senior author Tyler Hyungtaek Rim of Singapore Eye Research Institute and colleagues trained five algorithms to identify appropriate surgery candidates.

From these overlapping tools they built the high-performing ensemble classifier, training it on corneal tomography images, demographics data and data from other ophthalmic examinations of more than 10,000 patients.

The team internally validated the approach on data from more than 2,600 patients and subsequently validated it externally using data from more than 5,200 patients who received screening exams after the architecture’s development period.

“Our proposed machine learning model is expected to perform reliably because it was trained by a large population,” the authors concluded. “An automated analysis of preoperative data can provide a safe and reliable clinical decision for refractive surgery. In the future, this approach will facilitate standardized and automated selections of surgical choices.”

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.